Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Chianchinon May 29, 2021 9:06am
113 Views
Post# 33292214

RE:RE:RE:RE:RE:RE:Exelon & HUGE GROWING UNMET NEED

RE:RE:RE:RE:RE:RE:Exelon & HUGE GROWING UNMET NEEDAlways glad to help. Follow the following and if you sign up they will email you their BUY AND SELL day trade. 
Currently I hold Surf, twist, CRSP, Repare. They do intensive research in the future disruptive biotech space. GUD HAD A GREAT CHANCE to get involved  but they waisted millions and seven Years  and no profits. The whole biotech industry has changed several times upside down but GUD MNGT does not know. Meir did but no one listens. BMY trades at 10 PE for they have low growth potential, GUD would need to make $.50  to justify their current $5.25 share price. It may take them another seven Years. GUD In 2022 expected profit $.010 per share. 
ARK Genomic Revolution ETF
 
<< Previous
Bullboard Posts
Next >>